Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients

Abstract Objective The purpose of this study was to explore the population pharmacokinetic features of moxifloxacin in infected patients. Method A total of 37 Chinese adult infected patients were treated with intravenous moxifloxacin (400 mg/day). In total, 67 plasma samples of moxifloxacin were col...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2014-10, Vol.20 (10), p.621-626
Hauptverfasser: Zhu, Liqin, Wang, Nan, Yang, Wenjie, Zhang, Yuan, Zhao, Xuequn, Ji, Shuangmin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Objective The purpose of this study was to explore the population pharmacokinetic features of moxifloxacin in infected patients. Method A total of 37 Chinese adult infected patients were treated with intravenous moxifloxacin (400 mg/day). In total, 67 plasma samples of moxifloxacin were collected immediately after intravenous dripping and before administration on the 3rd, 4th or 5th day. A nonlinear mixed effect model was used to model the population pharmacokinetic (PK) behavior of moxifloxacin. The final population pharmacokinetic models were validated using the bootstrap method. Some covariates, including demographic characteristics and hematological and biological indicators, were analyzed. Results A structural model was developed based on a one-compartment model with intravenous infusion and first-order elimination. The typical population values of moxifloxacin for the pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume ( V ) were 12.9 L/h and 115 L, respectively. The inter-individual variabilities of CL and V were 36% and 28%, respectively. The covariates of WT influenced the CL and V values determined by the final model. Conclusion The present study developed population pharmacokinetic models for moxifloxacin in infected Chinese patients. The results detailed here could provide a reference for individualized moxifloxacin therapy in the clinical setting.
ISSN:1341-321X
1437-7780
DOI:10.1016/j.jiac.2014.06.001